Intas Pharmaceuticals Ltd.
Profile managed by Bizz IdDescription
Products
11 productsBrand: Jubereq (denosumab-desu). Denosumab biosimilar commercially available in the US (Accord BioPharma).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Osvyrti (denosumab-desu). Denosumab biosimilar commercially available in the US (Accord BioPharma). REMS program.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Accofil. Biosimilar marketed in the EU.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Filkri (filgrastim-laha). Biosimilar to Neupogen. Launched in the US by Accord BioPharma.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Immgolis Intri (golimumab-sldi) for infusion. Accord BioPharma (US).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Immgolis (golimumab-sldi). Accord BioPharma (US).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Ennumo (pegfilgrastim-pccg). Biosimilar to Neulasta. Accord BioPharma's second pegfilgrastim biosimilar (US).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Pelgraz. Pegfilgrastim biosimilar launched across Europe in 2018.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Udenyca (pegfilgrastim-cbqv). Accord BioPharma (US).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Hercessi (trastuzumab-strf). Accord BioPharma (US).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Imuldosa (ustekinumab-srlf). Accord BioPharma (US).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21